<div id="readability-page-1"><p>Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) have been assigned a consensus rating of &#34;Moderate Buy&#34; from the seventeen ratings firms that are currently  covering the company, MarketBeat.com reports. One investment analyst  has rated the stock with a sell rating, three have given a hold rating and thirteen have issued  a buy rating on  the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $38.7143.</p><div><p><span></span><span>Get <strong>Travere Therapeutics</strong> alerts:</span></p></div><ul><li>3 Under-the-Radar Healthcare Companies</li></ul><p>A number of research firms have issued reports on TVTX. Jefferies Financial Group  set a $35.00 target price on Travere Therapeutics in a research note on Wednesday, September 10th. Citigroup raised their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Wall Street Zen upgraded shares of Travere Therapeutics from a &#34;buy&#34; rating to a &#34;strong-buy&#34; rating in a research report on Saturday. Wells Fargo &amp; Company increased their price objective on shares of Travere Therapeutics from $27.00 to $35.00 and gave the company an &#34;overweight&#34; rating in a research note on Thursday, September 11th. Finally, Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of Travere Therapeutics in a research report on Wednesday, October 8th.</p><p><b>Get Our Latest Stock Report on TVTX</b></p><h2>Travere Therapeutics Stock Down 0.5%</h2><ul><li>Travere Therapeutics Still On The Rise After Encouraging Data </li></ul><p>NASDAQ TVTX opened at $34.83 on Monday. The business has a fifty day moving average price of $32.08 and a two-hundred day moving average price of $22.92. The stock has a market capitalization of $3.12 billion, a PE ratio of -32.86 and a beta of 0.89. Travere Therapeutics has a fifty-two week low of $12.91 and a fifty-two week high of $37.50. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. </p><p>Travere Therapeutics (NASDAQ:TVTX - Get Free Report) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.28 EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.59. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.The company had revenue of $164.86 million during the quarter, compared to analysts' expectations of $106.09 million. During the same quarter in the previous year, the firm earned ($0.70) EPS. Travere Therapeutics's revenue was up 162.1% on a year-over-year basis.  Equities analysts expect that  Travere Therapeutics will post -1.4 earnings per share for the current fiscal year. </p><h2>Insider Buying and Selling</h2><p>In other Travere Therapeutics news, CAO Sandra Calvin sold 67,115 shares of the stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the transaction, the chief accounting officer directly owned 48,545 shares in the company, valued at approximately $1,747,620. This trade represents a 58.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Also, CEO Eric M. Dube sold 92,872 shares of Travere Therapeutics stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $30.38, for a total value of $2,821,451.36. Following the sale, the chief executive officer directly owned 419,173 shares in the company, valued at $12,734,475.74. The trade was a 18.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 243,368 shares of company stock worth $7,910,972 in the last ninety days. Insiders own  4.06% of the company's stock. </p><h2>Institutional Inflows and Outflows</h2><p>A number of large investors have recently added to or reduced their stakes in TVTX. Penn Capital Management Company LLC grew its holdings in  Travere Therapeutics by 39.7% during the 3rd quarter. Penn Capital Management Company LLC now owns 27,004 shares of the company's stock worth $645,000 after acquiring an additional 7,680 shares during the last quarter.  CIBC Bancorp USA Inc. acquired a new position in shares of  Travere Therapeutics during the third quarter worth $225,000.  PharVision Advisers LLC bought a new stake in shares of  Travere Therapeutics in the third quarter worth $210,000.  Voloridge Investment Management LLC increased its holdings in  Travere Therapeutics by 18.7% in the third quarter. Voloridge Investment Management LLC now owns 883,672 shares of the company's stock valued at $21,120,000 after purchasing an additional 139,018 shares during the period.  Finally, Quarry LP increased its holdings in  Travere Therapeutics by 113.7% in the third quarter. Quarry LP now owns 14,960 shares of the company's stock valued at $358,000 after purchasing an additional 7,960 shares during the period. </p><h2>Travere Therapeutics Company Profile</h2> (Get Free Report)<p>Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Travere Therapeutics</li><li>Investing in Travel Stocks Benefits</li><li>Dave &amp; Buster’s Reversal Is in PLAY After Double-Bottom Breakout</li><li>Best Energy Stocks - Energy Stocks to Buy Now</li><li>3 Finance Stocks to Buy on Rising 10-Year Treasury Rates</li><li>3 Healthcare Dividend Stocks to Buy</li><li>Disney's $1 Billion Deal Brings Its Magic to OpenAI</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VFZUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Travere Therapeutics Right Now?</h2><p>Before you consider Travere Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Travere Therapeutics wasn't on the list.</p><p>While Travere Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

TVTX

<p>Travere Therapeutics, Inc. (NASDAQ:TVTX) has received a consensus rating of "Moderate Buy" from 17 brokerages, with an average price target of $38.71. Analysts have varied ratings, including sell, hold, and buy. Recent insider trading includes significant stock sales by the CAO and CEO. Institutional investors have adjusted their stakes in the company, with notable increases and new positions.</p>

Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Average Recommendation of "Moderate Buy" from Brokerages